Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET
Company Participants
James Caruso - President and Chief Executive Officer
Andrei Shustov - Senior Vice President, Medical
Jarrod Longcor - Chief Operating Officer
Shane Lea - Chief Commercial Officer
Chad Kolean - Chief Financial Officer
Conference Call Participants
Ahu Demir - Ladenburg Thalmann
Jeff Jones - Oppenheimer
Jonathan Aschoff - ROTH MKM
Operator
Good morning and welcome to Cellectar Biosciences First Quarter 2024 Earnings Call. Today's call is being recorded.
Before we begin, I would like to remind everyone that statements made during this call relating to Cellectar’s expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions. Actual outcomes and results are subject to risks and uncertainties that could differ materially believe from those forecasts due to the impact of many factors beyond the control of Cellectar.
The company assumes no obligation to update or supplements any forward-looking statements whether as a result of new information, future events or otherwise. Participants are directed to the cautionary notes set forth in today's press release, which is available on the Investor Relations portion of the company's website, as well as the risk factors set forth in Cellectar’s annual reports filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements.
At this time, I would like to turn the call over to Jim Caruso, President and Chief Executive Officer of Cellectar. Mr. Caruso, please go ahead.
James Caruso
Thank you, operator and good morning everyone. It is my pleasure to be here with you to report our Q1 results and provide a corporate update. With me today are Dr. Andrei Shustov, Senior Vice President, Medical; Jarrod Longcor, Chief Operating Officer; Shane Lea, Chief Commercial Officer; and Chad Kolean, our Chief Financial Officer.
As you know, we recently completed our 2023 annual earnings call in which we reviewed a highly productive year for the company including the announcement of detailed top line data from our WM pivotal study and reiterated guidance for a data update in Q2. I am pleased to report that we remain on track for a Q2 data announcement for the fully enrolled study patient population. We plan to press release this data in June and review in greater detail on a key opinion leader call scheduled for the same day.